Bernard Tawfik1, Timothy S Pardee2, Scott Isom3, Sarunas Sliesoraitis1, Allison Winter1, Julia Lawrence2, Bayard L Powell2, Heidi D Klepin4. 1. Department of Internal Medicine, Wake Forest Baptist Health, Winston-Salem, NC, USA. 2. Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA. 3. Division of Public Health Sciences, Department of Biostatistics, Wake Forest School of Medicine, Winston-Salem, NC, USA. 4. Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA. Electronic address: hklepin@wakehealth.edu.
Abstract
INTRODUCTION: Our goal was to characterize comorbidities among adults receiving intensive therapy for AML, and investigate their association with outcomes. METHODS: We retrospectively analyzed 277 consecutive patients with newly diagnosed AML treated intensively at the Comprehensive Cancer Center of Wake Forest University from 2002 to 2009. Pretreatment comorbidities were identified by ICD-9 codes and chart review. Comorbidity burden (modified Charlson Comorbidity Index [CCI]) and specific conditions were analyzed individually. Outcomes were overall survival (OS), remission, and 30-day mortality. Covariates included age, gender, cytogenetic characteristics, hemoglobin, white cell count, lactate dehydrogenase, body mass index, and insurance type. Cox proportional hazards models were used to evaluate OS; logistic regression was used for remission and 30-day mortality. RESULTS: In this series, 144 patients were ≥ 60 years old (median age 70 years, median survival 8.7 months) and 133 were <60 years (median age 47 years, median survival 23.1 months). Older patients had a higher comorbidity burden (CCI≥1 58% versus 26%, P<0.001). Prevalent comorbid conditions differed by age (diabetes 19.2% versus 7.5%; cardiovascular disease 12.5% versus 4.5%, for older versus younger patients, respectively). The CCI was not independently associated with OS or 30-day mortality in either age group. Among older patients, diabetes was associated with higher 30-day mortality (33.3% vs. 12.0% in diabetic vs. non-diabetic patients, p=0.006). Controlling for age, cytogenetic characteristics and other comorbidities, the presence of diabetes increased the odds of 30-day mortality by 4.9 (CI 1.6-15.2) times. DISCUSSION: Diabetes is adversely associated with 30-day survival in older AML patients receiving intensive therapy.
INTRODUCTION: Our goal was to characterize comorbidities among adults receiving intensive therapy for AML, and investigate their association with outcomes. METHODS: We retrospectively analyzed 277 consecutive patients with newly diagnosed AML treated intensively at the Comprehensive Cancer Center of Wake Forest University from 2002 to 2009. Pretreatment comorbidities were identified by ICD-9 codes and chart review. Comorbidity burden (modified Charlson Comorbidity Index [CCI]) and specific conditions were analyzed individually. Outcomes were overall survival (OS), remission, and 30-day mortality. Covariates included age, gender, cytogenetic characteristics, hemoglobin, white cell count, lactate dehydrogenase, body mass index, and insurance type. Cox proportional hazards models were used to evaluate OS; logistic regression was used for remission and 30-day mortality. RESULTS: In this series, 144 patients were ≥ 60 years old (median age 70 years, median survival 8.7 months) and 133 were <60 years (median age 47 years, median survival 23.1 months). Older patients had a higher comorbidity burden (CCI≥1 58% versus 26%, P<0.001). Prevalent comorbid conditions differed by age (diabetes 19.2% versus 7.5%; cardiovascular disease 12.5% versus 4.5%, for older versus younger patients, respectively). The CCI was not independently associated with OS or 30-day mortality in either age group. Among older patients, diabetes was associated with higher 30-day mortality (33.3% vs. 12.0% in diabetic vs. non-diabeticpatients, p=0.006). Controlling for age, cytogenetic characteristics and other comorbidities, the presence of diabetes increased the odds of 30-day mortality by 4.9 (CI 1.6-15.2) times. DISCUSSION: Diabetes is adversely associated with 30-day survival in older AMLpatients receiving intensive therapy.
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: Diabetes Care Date: 2010-07 Impact factor: 19.112
Authors: Antoine J Harb; Wei Tan; Gregory E Wilding; LaurieAnn Ford; Sheila N J Sait; AnneMarie W Block; Maurice Barcos; Paul K Wallace; Eunice S Wang; Meir Wetzler Journal: Cancer Date: 2009-06-01 Impact factor: 6.860
Authors: Naeem A Ali; James M O'Brien; William Blum; John C Byrd; Rebecca B Klisovic; Guido Marcucci; Gary Phillips; Clay B Marsh; Stanley Lemeshow; Michael R Grever Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: John N Allan; Gail J Roboz; Gulce Askin; Ellen Ritchie; Joseph Scandura; Paul Christos; Duane C Hassane; Monica L Guzman Journal: Leuk Lymphoma Date: 2017-07-18
Authors: Joel M Michalski; Elizabeth R Lyden; Andrea J Lee; Zaid S Al-Kadhimi; Lori J Maness; Krishna Gundabolu; Vijaya Raj Bhatt Journal: Future Oncol Date: 2019-06-07 Impact factor: 3.404
Authors: Tamjeed Ahmed; Abby L Koch; Scott Isom; Heidi D Klepin; Jonathan M Bishop; Leslie R Ellis; Dmitriy Berenzon; Dianna Howard; Susan Lyerly; Bayard L Powell; Timothy S Pardee Journal: Leuk Res Date: 2017-09-27 Impact factor: 3.156